Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyong Joo | - |
dc.contributor.author | Cho, Jae Hee | - |
dc.contributor.author | Lee, Sang Hyub | - |
dc.contributor.author | Song, Si Young | - |
dc.contributor.author | Lee, Kwang Hyuk | - |
dc.contributor.author | Jeong, Seok | - |
dc.contributor.author | Ryu, Ji Kon | - |
dc.contributor.author | Woo, Sang Myung | - |
dc.contributor.author | Bang, Seungmin | - |
dc.contributor.author | Lee, Jong Kyun | - |
dc.contributor.author | Lee, Tae Hoon | - |
dc.contributor.author | Paik, Woo Hyun | - |
dc.contributor.author | Kim, Yong Tae | - |
dc.contributor.author | Lee, Woo Jin | - |
dc.date.accessioned | 2021-08-11T14:24:22Z | - |
dc.date.available | 2021-08-11T14:24:22Z | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.issn | 1432-0843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7188 | - |
dc.description.abstract | Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Springer Verlag | - |
dc.title | Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s00280-017-3421-7 | - |
dc.identifier.wosid | 000411555500015 | - |
dc.identifier.bibliographicCitation | Cancer Chemotherapy and Pharmacology, v.80, no.4, pp 799 - 805 | - |
dc.citation.title | Cancer Chemotherapy and Pharmacology | - |
dc.citation.volume | 80 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 799 | - |
dc.citation.endPage | 805 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | CARCINOMAS | - |
dc.subject.keywordPlus | NEOPLASMS | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | RADIANT-3 | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Everolimus | - |
dc.subject.keywordAuthor | Pancreatic neuroendocrine tumor | - |
dc.subject.keywordAuthor | World Health Organization classification | - |
dc.subject.keywordAuthor | Tumor grade | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.